Comparison of first trimester, second trimester and integrated down's syndrome screening results in unaffected pregnancies

Clinical Chemistry and Laboratory Medicine

Volumn 40, Issue 6, 2002, Pages 600-603

  Canini, Silvana ^a   Prefumo, Federico ^a   Famularo, Luciano ^a   Venturini, Pier Luigi ^a   Palazzese, Valter ^a   De Biasio, Pierangela ^a  

^a Laboratorio di Analisi   (Italy)

Author keywords

Nuchal translucency thickness; Prenatal screening

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; PROTEIN A;

ADULT; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CHILDBIRTH; CONTROLLED STUDY; CORRELATION FUNCTION; DOWN SYNDROME; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MEDICAL ETHICS; POPULATION RESEARCH; PREGNANCY DISORDER; PREGNANCY TERMINATION; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCREENING TEST; SECOND TRIMESTER PREGNANCY;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; DOWN SYNDROME; ESTRIOL; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 0036336724     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2002.103     Document Type: Article

References (16)

1. Maternal serum screening for Down's syndrome in early pregnancy
2. Fetal nuchal translucency: Ultrasound screening for chromosomal effects in first trimester of pregnancy
3. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestion
4. Combined ultrasound and biochemistry in first trimester screening for Down's syndrome
5. First-trimester screening for Down syndrome using nuchal translucency measurement with β-hCG and PAPP-A between 10 and 13 weeks of pregnancy - The combined test
6. Integrated screening for Down's syndrome based on tests performed during the first and second trimester
7. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy
8. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β human chorionic gonadotropin and pregnancy-associated plasma protein-A
9. Screening biochimico per la sindrome di Down sul siero materno nel secondo trimestre di gravidanza
10. Extent of correlation between first and second trimester markers for Down's syndrome screening
11. Performing screening for Down's syndrome - A search for the family's values
12. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome
13. Combined first trimester nuchal translucency and second trimester screening tests among normal pregnancies
14. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome
15. Calculating correct Down's syndrome risks
16. Screening for Down's syndrome: Effects, safety, and cost effectiveness of first and second trimester strategies